SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : AFFYMETRIX (AFFX)
AFFX 14.010.0%Apr 1 5:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Pierre Borczuk who wrote (420)7/8/1997 8:04:00 PM
From: biowa   of 1728
 
Pierre,

>>Sounds like many many years of clinical trials <<

IMO, if the products are already FDA-approved, unnecessary to re-trial; clinical outcomes monitoring will merely "refocus" the use of these products. Also IMO, if the products are not yet approved, genotyping may help explain mixed results and improve PIII focus on target populations, in fact potentially reducing clinical trial durations. All hypothetical at this point, but a good reason to keep your eye on AFFX and its competitors.

biowa
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News